Biopharmaceutical benchmarks 2006 (original) (raw)

• Lawrence, S. Biotech drug market steadily expands. Nat. Biotechnol. 23, 1466 (2005).
  Article CAS Google Scholar
• Pavlou, A. & Belsey, M. The therapeutic antibody market to 2008. Eur. J. Pharm. Biopharm. 59, 389–396 (2005).
  Article Google Scholar
• Pavlou, A. & Reichert, J. Recombinant protein therapeutics—success rates, market trends and values to 2010. Nat. Biotechnol. 22, 1513–1519 (2004).
  Article CAS Google Scholar
• Walsh, G. Biopharmaceutical benchmarks—2003. Nat. Biotechnol. 21, 865–870 (2003).
  Article CAS Google Scholar
• World Health Organization. Diabetes Now http://www.idf.org/webdata/docs/diabetes_888k_version.pdf (2004).
• Kjeldsen, T. Yeast secretory expression of insulin precursors. Appl. Microbiol. Biotechnol. 54, 277–286 (2000).
  Article CAS Google Scholar
• Walsh, G. Therapeutic insulins and their large-scale manufacture. Appl. Microbiol. Biotechnol. 67, 151–159 (2005).
  Article CAS Google Scholar
• Brown, M., Martin, G., Jones, S. & Akomeah, F. Dermal and transdermal drug delivery systems: current and future prospects. Drug Deliv. 13, 175–187 (2006).
  Article CAS Google Scholar
• Chen, Y. et al. Transdermal protein delivery by a coadministered peptide identified via phage display technology. Nat. Biotechnol. 24, 455–460 (2006).
  Article CAS Google Scholar
• Hamman, J., Enslin, G.M. & Kotze, A.F. Oral delivery of peptide drugs—barriers and developments. BioDrugs 19, 165–177 (2005).
  Article CAS Google Scholar
• Orive, G., Hernández, R.M., Rodríguez Gascón, A., Domínguez-Gil, A. & Pedraz, J.L. Drug delivery in biotechnology: present and future. Curr. Opin. Biotechnol. 14, 659–664 (2003).
  Article CAS Google Scholar
• Upsher Smith Laboratories Inc. Fortical full prescribing information. http://www.upsher-smith.com/PDFs/forticalpi.pdf (2005).
• Patton, J.S., Bukar, J. & Nagarajan, S. Inhaled insulin. Adv. Drug Deliv. Rev. 35, 235–247 (1999).
  Article CAS Google Scholar
• Pfizer/Aventis. Exubera European Public Assessment Report. http://www.emea.eu.int/humandocs/PDFs/EPAR/exubera/058806en1.pdf (2006).
• Wildt, S. & Gerngross, T. The humanization of _N_-glycosylation pathways in yeast. Nat. Rev. Microbiol. 3, 119–128 (2005).
  Article CAS Google Scholar
• Gomord, W., Chamberlain, P., Jefferis, R. & Faye, L. Biopharmaceutical production in plants: problems, solutions and opportunities. Trends Biotechnol. 23, 559–565 (2005).
  Article CAS Google Scholar
• Chen, M. et al. Modification of plant _N_-glycan processing: the future of producing therapeutic protein by transgenic plants. Med. Res. Rev. 25, 343–360 (2005).
  Article CAS Google Scholar
• Gerngross, T.U. Advances in the production of human therapeutic proteins in yeasts and filamentous fungi. Nat. Biotechnol. 22, 1409–1414 (2004).
  Article CAS Google Scholar
• Jarvis, D. Developing baculovirus-insect cell expression systems for humanized recombinant glycoprotein production. Virology 310, 1–7 (2003).
  Article CAS Google Scholar
• Li, H. et al. Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat. Biotechnol. 24, 210–215 (2006).
  Article CAS Google Scholar
• Werten, M.W., Van de Bosch, T.J., Wind, R.D., Mooibroek, H. & De Wolf, F.A. High-yield secretion of recombinant gelatins by Pichia pastoris. Yeast 15, 1087–1096 (1999).
  Article CAS Google Scholar
• Butler, M. Animal cell cultures: recent achievements and perspectives in the production of biopharmaceuticals. Appl. Microbiol. Biotechnol. 68, 283–291 (2005).
  Article CAS Google Scholar
• CHMP (2006) Press release: Questions and answers on recommendation for refusal of marketing application for ATRYN (Committee for Medicinal Products for Human Use, London, 2006).
• Ivarie, R. Competitive bioreactor hens on the horizon. Trends Biotechnol. 24, 99–101 (2006).
  Article CAS Google Scholar
• Zhu, L. et al. Production of human monoclonal antibody in eggs of chimeric chickens. Nat. Biotechnol. 23, 1159–1169 (2005).
  Article CAS Google Scholar
• Dyck, M. et al. Seminal vesicle production and secretion of growth hormone into seminal fluid. Nat. Biotechnol., 17, 1087–1090 (1999).
  Article CAS Google Scholar
• Ben-Maimon, C. & Garnick, R. Biogenerics at the crossroads. Nat. Biotechnol. 24, 268–269 (2006).
  PubMed Google Scholar
• Diliberti, C. The best targets for biogenerics. BioPharm International 19, 50–64 (2006).
  CAS Google Scholar
• Fox, J. Sandoz sues FDA over delay in first biogeneric approval. Nat. Biotechnol. 23, 1327–1328 (2005).
  Article CAS Google Scholar
• Peng, Z. The genesis of Gendicine. BioPharm International 17, 42–49 (2004).
  Google Scholar
• Peng, Z. Current status of Gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum. Gene Ther. 16, 1016–1027 (2005).
  Article CAS Google Scholar
• Wilson, J. Gendicine: the first commercial gene therapy product. Hum. Gene Ther. 16, 1014 (2005).
  Article CAS Google Scholar
• Verma, I. & Weitzman, M. Gene therapy: twenty first century medicine. Annu. Rev. Biochem. 74, 711–738 (2005).
  Article CAS Google Scholar
• Vidal, L., Blagden, S., Attard, G. & deBono, J. Making sense of antisense. Eur. J. Cancer 41, 2812–2818 (2005).
  Article CAS Google Scholar
• Khan, A. Ribozyme: a clinical tool. Clin. Chim. Acta 367, 20–27 (2006).
  Article CAS Google Scholar
• Dallas, A. & Vlassov, A. RNAi: a novel antisense technology and its therapeutic potential. Med. Sci. Monit. 12, RA67–RA74 (2006).
  CAS PubMed Google Scholar
• Jana S, Chakraborty C, Nandi S, Deb JK. RNA interference: potential therapeutic targets. Appl. Microbiol. Biotechnol. 65, 649–657 (2004).
  Article CAS Google Scholar
• Jana, S., Chakraborty, C., Nandi, S. & Deb, J.K. RNA interference: potential therapeutic targets. Appl. Microbiol. Biotechnol. 65, 649–657 (2004).
  Article CAS Google Scholar
• Zimmermann, T.S. et al. RNAi-mediated silencing in non-human primates. Nature 441, 111–114 (2006).
  Article CAS Google Scholar
• Hermeling, S., Schellekens, H., Crommelin, D. & Jiskoot, W. Micelle-associated protein in Epoetin formulations: a risk factor for immunogenicity? Pharm. Res. 20, 1903–1907 (2003).
  Article CAS Google Scholar
• Villalobos, A.P., Gunturi, S.R. & Heavner, G.A. Interaction of polysorbate 80 with erythropoietin: a case study in protein-surfactant interactions. Pharm. Res. 22, 1186–1194 (2005).
  Article CAS Google Scholar
• Hermeling, S., Jiskoot, W., Crommelin, D. & Schellekens, H. Reaction to the paper: interaction of polysorbate 80 with erythropoietin: a case study in protein-surfactant interactions. Pharm. Res. 23, 641–642 (2006).
  Article CAS Google Scholar
• Lim, L.C. Acquired red cell aplasia in association with the use of recombinant erythropoietin in chronic renal failure. Hematology (Am. Soc. Hematol. Educ. Program) 10, 255–259 (2005).
  CAS Google Scholar
• Sheridan, C. TeGenero fiasco prompts regulatory rethink. Nat. Biotechnol. 24, 475–476 (2006).
  Article CAS Google Scholar
• Proske, D., Blank, M., Buhmann, R. & Resch, A. Aptamers—basic research, drug development, and clinical applications. Appl. Microbiol. Biotechnol. 69, 367–374 (2005).
  Article CAS Google Scholar
• Nimjee, S.M., Rusconi, C.P. & Sullenger, B.A. Aptamers, an emerging class of therapeutics. Annu. Rev. Med., 56, 555–583 (2005).
  Article CAS Google Scholar
• Hey, T., Fiedler, E., Rudolph, R. & Fiedler, M. Artificial, non-antibody binding proteins for pharmaceutical and industrial applications. Trends Biotechnol, 23, 514–522 (2005).
  Article CAS Google Scholar
• Binz, H.K., Amstutz, P. & Pluckthun, A. Engineering novel binding proteins from nonimmunoglobulin domains. Nat. Biotechnol. 23, 1257–1268 (2005).
  Article CAS Google Scholar